Background/Aims: Diabetic nephropathy is one of the primary diseases of refractory renal failure and heads the list of patients undergoing dialysis. Therefore, it is very important to get treatment in incipient nephropathy. Methods: Twenty-seven patients in incipient diabetic nephropathy of type 2 diabetes mellitus who showed signs of microalbuminuria were randomly, but not blindly, assigned to two groups, either the beraprost sodium (PGI2) group or the control group, and effects of the preparation on urinary albumin excretion or other parameters were examined for 24 months. Results: Urinary albumin excretion was significantly decreased after 18 months in beraprost sodium group; however, there was no change in the control group. Difference was observed between the two groups after month 12; however, it was not significant (p = 0.0673 at month 24). Three factors that affect urinary albumin excretion, e.g. blood pressure, blood sugar and protein intake, were almost constant during the study period. The level of creatinine clearance was significantly decreased in beraprost sodium group after 24 months as compared with the control group. Conclusion: In this study, we found that the long-term 24-month administration of PGI2 preparation, beraprost sodium, decreased albuminuria in patients of incipient diabetic nephropathy. The possible mechanisms are that the PGI2 may have alleviated constriction effect of angiotensin II on efferent glomerular arteriole and attenuated glomerular hyperfiltration, and inhibited growth of mesangial cells by platelet-derived growth factor as well.

Keywords:
Type 2 diabetes mellitus, Microalbuminuria, Beraprost sodium, Hypertension, Protein intake
1.
Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M: PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 1995;48:111–117.
2.
Haider A, Oh P, Peloso PM: An evidence-based review of ACE inhibitors in incipient diabetic nephropathy. Can J Clin Pharmacol 2000;7:115–119.
3.
Arima S, Ren YL, Juncos LA, Carretero OA, Ito S: Glomerular prostaglandins modulate vascular reactivity of the downstream efferent arterioles. Kidney Int 1994;45:650.
4.
Craven PA, Caines MA, DeRubertis FR: Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: Relationship to the hyperfiltration of early diabetes. Metabolism 1987;36:95–103.
5.
Masumura H, Kunitada S, Irie K, Ashida S, Abe Y: A thromboxaneA2 synthetase inhibitor retards hypertensive rat diabetic nephropathy. Eur J Pharmacol 1992;210:163–172.
6.
Feldt-Rasmussen B, Mathiesen ER, Hegedus L, Deckert T: Kidney function during 12 months of strict metabolic control in insulin-dependent diabetic patients with incipient nephropathy. N Engl J Med 1986;314:665–670.
7.
The Kroc Collaborative Study Group: Blood glucose control and the evolution of diabetic retinopathy and albuminuria: A preliminary multicenter trial. N Engl J Med 1984;311:365–372.
8.
Feldt-Rasmussen B, Mathiesen ER, Deckert T: Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986;ii: 1300–1304.
9.
The Euclid Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787–1792.
10.
Christensen CK, Mogensen CE: Anthypertensive treatment: Long-term reversal of progression of albuminuria in incipient diabetic nephropathy: A longitudinal study of renal function. Complications 1987;1:45–52.
11.
Melbourne Diabetic Nephropathy Study Group: Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 1991;302:210–216.
12.
Pedersen MM, Winther E, Mogensen CE: Reducing protein in the diabetic diet. Diabète Métabol (Paris) 1990;16:454–459.
13.
Cohen D, Dodds R, Viberti G: Effect of protein restriction in insulin dependent diabetics at risk of nephropathy. BMJ 1987;294:795–798.
14.
Brouhard BH, Lagrone L: Effect of dietary protein restriction on functional renal reserve in diabetic nephropathy. Am J Med 1990;89:427–431.
15.
Maroni BJ, Steinman TI, Mitch WE: A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985;27:58–65.
16.
Moorthead JF: Lipids and progressive kidney disease. Kidney Int 1991;39(suppl 31):S35–S40.
17.
Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O’Donnell MP: Hyperlipidemia and progressive renal disease. Kidney Int 1991;39:S41–S48.
18.
Keane WF: Lipids and the kidney. Kidney Int 1994;46:910–920.
19.
Parving HH, Osterby R, Anderson PW, Hsueh WA: Diabetic nephropathy; in Brenner BM (ed): The Kidney, ed 5. Philadelphia, Saunders, 1996, pp 1864–1892.
20.
Koh E, Morimoto S, Jiang B, Inoue T, Nabata T, Kitano S, Yasuda O, Fukuo K, Ogihara T: Effects of beraprost sodium, a stable analogue of prostacyclin, on hyperplasia, hypertrophy and glycosaminoglycan synthesis of rat aortic smooth muscle cells. Artery 1993;20:242–252.
21.
Villa E, Pabano A, Ruilope LM, Garcia-Robles R: Effects of cicaprost and fosinopril on the progression of rat diabetic nephropathy. Am J Hypertens 1997;10:202–208.
22.
Wang LN, Tang Z, Shou I, Fukui M, Tomino Y: Effect of the PGI2 analog beraprost sodium on glomerular prostanoid synthesis in rats with streptozotocin-induced diabetes. Nephron 1996;73:637–643.
23.
Harrison HE, Reece AH, Johnson M: Decreased vascular prostacyclin in experimental diabetes. Life Sci 1978;23:351–356.
24.
Gragnoli G, Signorini AM, Tanganelli I, Fondelli C, Borgogni P, Borgogni L, Vattimo A, Ferrari F, Guercia M: Prevalence of glomerular hyperfiltration and nephromegaly in normo- and microalbuminuric type 2 diabetic patients. Nephron 1993;65:206–211.
25.
Craven PA, Melhem MF, Derubertis FR: Thromboxane in the pathogenesis of glomerular injury in diabetes. Kidney Int 1992;42:937–946.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.